MedPath

Management of early changes in eye (retina) due to diabetic

Phase 2
Completed
Conditions
Retinal disorders in diseases classified elsewhere. Ayurveda Condition: Madhumehajanya Timir,
Registration Number
CTRI/2015/10/006293
Lead Sponsor
Institute for Post Graduate Teaching and Research in Ayurveda Gujarat Ayurved University
Brief Summary

This study is a randomized parallel clinical study to evaluate the efficacy Ayurvedic Treatment Protocol in patients of BDR.

Detailed Description

Not available

Recruitment & Eligibility

Status
Completed
Sex
All
Target Recruitment
100
Inclusion Criteria

Patients willing for the treatment Patients of 30-70 yrs having Type-1(Non insulin dependent) with or without visual disturbances, but the detectable ophthalmoscopic features of BDR Patient of Type-1 (Non insulin dependent) with blood sugar level, FBS- 126 to 220 mg/dl or PPBS-180 to 300 mg/dl with ongoing treatment.

Exclusion Criteria
  • Patients who are extremely debilitating and those who are not able to withstand treatment procedures.
  • Patients of Sahaja Prameha (Hereditary).
  • Patients of Type-1 Diabetes or the patients of Type-2 Diabetes taking Insulin.
  • High Risk DR or those requiring emergency intervention.
  • which interfere with ophthalmoscopical findings.
  • Patients having other ocular pathologies like glaucoma, high myopia etc.
  • Hypertensive Retinopathy and DR associated with pregnancy.

Study & Design

Study Type
Interventional
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Sign and Symptoms of BDR will improve with treatmentSign and Symptoms of BDR will improve with treatment within 3 months
Secondary Outcome Measures
NameTimeMethod
blurring of vision improve90 days

Trial Locations

Locations (1)

IPGT and RA Hospital

🇮🇳

Jamnagar, GUJARAT, India

IPGT and RA Hospital
🇮🇳Jamnagar, GUJARAT, India
Dr Deepak K Pawar
Principal investigator
7359906935
drdeep29@gmail.com

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.